AUA 2014 - Results from #20

#AUA14 - Nadir testosterone on ADT predicts for time to castrate resistant progression: A secondary analysis of the PR-7 intermittent vs continuous ADT trial - Session Highlights May 21, 2014

#AUA14 - Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort - Session Highlights May 21, 2014

#AUA14 - An exploratory analysis of the Genomic Prostate Score as a predictor of local or metastatic progression in men who experience biochemical recurrence after surgery for organ-confined prostate cancer - Session Highlights May 21, 2014

#AUA14 - Validation of a genomic classifier for predicting clinical progression following post-operative radiation therapy in high-risk prostate cancer - Session Highlights May 21, 2014

#AUA14 - Variation of serum prostate-specific antigen levels for men with prostate cancer managed with active surveillance - Session Highlights May 21, 2014

#AUA14 - Free serum testosterone versus total testosterone as surrogate marker for the clinical benefit of androgen suppression in prostate cancer patients - Session Highlights May 21, 2014

#AUA14 - An indirect treatment comparison and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer post chemotherapy - Session Highlights May 21, 2014

#AUA14 - Impact of prior endocrine therapy on clinical benefit of abiraterone acetate in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302 - Session Highlights May 21, 2014

#AUA14 - Efficacy and long-term safety analysis of study COU-AA-302: Abiraterone acetate plus prednisone in chemotherapy-naïve metastatic castration-resistant prostate cancer - Session Highlights May 21, 2014

#AUA14 - Sipuleucel-T-induced antigen spread: immune response to prostate-specific antigen correlates with improved overall survival - Session Highlights May 21, 2014

#AUA14 - State-of-the-Art Lecture: Clinical implications of The Cancer Genome Atlas Project on muscle-invasive bladder cancer - Session Highlights May 21, 2014

#AUA14 - MRI–ultrasound fusion targeted prostate biopsy: The importance of biopsying outside the MRI lesion - Session Highlights May 21, 2014

#AUA14 - Prognostic factors for disease-free survival after complete metastasectomy for recurrent renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience - Session Highlights May 21, 2014

#AUA14 - Cancer-specific survival and predictors in patients with cT3b kidney cancer: Data of the IRCVT RCC venous thrombus consortium - Session Highlights May 21, 2014

#AUA14 - Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior vena cava: A propensity score matched analysis - Session Highlights May 21, 2014

#AUA14 - Statin use is an independent predictor of improved survival in patients with metastatic renal cell carcinoma - Session Highlights May 21, 2014

#AUA14 - Partial nephrectomy is equivalent to active surveillance in preserving renal function for patients with small renal masses - Session Highlights May 21, 2014

#AUA14 - Performance of primary radical cystectomy and risk of pathologic upstaging in patients with Stage I high grade urothelial carcinoma of the bladder: A National Cancer Database analysis - Session Highlights May 21, 2014

#AUA14 - The risk of congenital birth defects is not associated with semen parameters - Session Highlights May 21, 2014

#AUA14 - Semen quality, infertility, and mortality in the United States - Session Highlights May 21, 2014

Page 2 of 9